SCHEMBL29947152

SCHEMBL29947152

CN(C)S(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc(F)c2N2CCC(Oc3ncc(Cl)cc3F)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN2 Q8IZK6 1/20 0.51
FPR2 P25090 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
CCR2 P41597 3/20 0.40
PIK3CA P42336 2/20 0.39
MAPK14 Q16539 1/20 0.39
SCN8A Q9UQD0 4/20 0.37
SCN1A P35498 3/20 0.37
KCNH2 Q12809 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
MAP3K20 Q9NYL2 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CCR4 P51679 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29947304 0.89 MCOLN2 (0.51) MCOLN2FPR2PROKR1CCR2PIK3CA
SCHEMBL29947135 0.82 MCOLN2 (0.48) MCOLN2PIK3CASCN8ASCN1AALDH1A1
SCHEMBL29947194 0.81 MCOLN2 (0.45) MCOLN2CYP3A4SLC40A1
SCHEMBL29948512 0.77 MCOLN2 (0.56) MCOLN2ALDH1A1KDM4ELMNAHPGD
SCHEMBL29947162 0.77 MCOLN2 (0.62) MCOLN2CCR2MAPK14SCN8AALDH1A1
SCHEMBL29932019 0.76 MCOLN2 (0.49) MCOLN2ALDH1A1KDM4ELMNAHPGD
SCHEMBL23057224 0.76 MCOLN2 (0.76) MCOLN2ALDH1A1KDM4ELMNAHPGD
SCHEMBL31036862 0.76 MCOLN2 (0.63) MCOLN2PIK3CASCN8ASCN1AALDH1A1
SCHEMBL23536282 0.74 RECQL (0.54) MCOLN2ALDH1A1KDM4ELMNAMEN1
SCHEMBL29947136 0.73 FPR2 (0.45) FPR2PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. 2024-08-01 US disclosed
EP-4337206-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF Libra Therapeutics, Inc. (US) 2024-03-20 EP disclosed
WO-2022240992-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF TRPM2, TRPM7, TRPM8 MCOLN2 9/4885FPR2 932/4885PROKR1 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.